The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
Anaplastic lymphoma kinase (ALK) inhibitors are currently being considered in neuroblastoma (NB), but its acquired resistance is reported in non-small cell lung cancers. Here, the authors have found PIM1 overexpression decreases sensitivity to ALK inhibitors in NB and combined ALK and PIM1 inhibitio...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2019-11-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-019-13315-x |
| id |
doaj-f2be0a65707b41b5b2ef0367cf79b3cb |
|---|---|
| record_format |
Article |
| spelling |
doaj-f2be0a65707b41b5b2ef0367cf79b3cb2021-05-11T11:31:15ZengNature Publishing GroupNature Communications2041-17232019-11-0110111310.1038/s41467-019-13315-xThe targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN statusRicky M. Trigg0Liam C. Lee1Nina Prokoph2Leila Jahangiri3C. Patrick Reynolds4G. A. Amos Burke5Nicola A. Probst6Miaojun Han7Jamie D. Matthews8Hong Kai Lim9Eleanor Manners10Sonia Martinez11Joaquin Pastor12Carmen Blanco-Aparicio13Olaf Merkel14Ines Garces de los Fayos Alonso15Petra Kodajova16Simone Tangermann17Sandra Högler18Ji Luo19Lukas Kenner20Suzanne D. Turner21Division of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeCancer Center, Texas Tech University Health Sciences Center School of MedicineDepartment of Paediatric Oncology, Box 181, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical CampusDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeExperimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO)Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO)Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO)Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of ViennaDepartment of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of ViennaUnit of Laboratory Animal Pathology, University of Veterinary Medicine ViennaUnit of Laboratory Animal Pathology, University of Veterinary Medicine ViennaUnit of Laboratory Animal Pathology, University of Veterinary Medicine ViennaLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of HealthDepartment of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of ViennaDivision of Cellular and Molecular Pathology, Department of Pathology, University of CambridgeAnaplastic lymphoma kinase (ALK) inhibitors are currently being considered in neuroblastoma (NB), but its acquired resistance is reported in non-small cell lung cancers. Here, the authors have found PIM1 overexpression decreases sensitivity to ALK inhibitors in NB and combined ALK and PIM1 inhibition enhances anti-tumour efficacy in vitro and in PDX models.https://doi.org/10.1038/s41467-019-13315-x |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Ricky M. Trigg Liam C. Lee Nina Prokoph Leila Jahangiri C. Patrick Reynolds G. A. Amos Burke Nicola A. Probst Miaojun Han Jamie D. Matthews Hong Kai Lim Eleanor Manners Sonia Martinez Joaquin Pastor Carmen Blanco-Aparicio Olaf Merkel Ines Garces de los Fayos Alonso Petra Kodajova Simone Tangermann Sandra Högler Ji Luo Lukas Kenner Suzanne D. Turner |
| spellingShingle |
Ricky M. Trigg Liam C. Lee Nina Prokoph Leila Jahangiri C. Patrick Reynolds G. A. Amos Burke Nicola A. Probst Miaojun Han Jamie D. Matthews Hong Kai Lim Eleanor Manners Sonia Martinez Joaquin Pastor Carmen Blanco-Aparicio Olaf Merkel Ines Garces de los Fayos Alonso Petra Kodajova Simone Tangermann Sandra Högler Ji Luo Lukas Kenner Suzanne D. Turner The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status Nature Communications |
| author_facet |
Ricky M. Trigg Liam C. Lee Nina Prokoph Leila Jahangiri C. Patrick Reynolds G. A. Amos Burke Nicola A. Probst Miaojun Han Jamie D. Matthews Hong Kai Lim Eleanor Manners Sonia Martinez Joaquin Pastor Carmen Blanco-Aparicio Olaf Merkel Ines Garces de los Fayos Alonso Petra Kodajova Simone Tangermann Sandra Högler Ji Luo Lukas Kenner Suzanne D. Turner |
| author_sort |
Ricky M. Trigg |
| title |
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status |
| title_short |
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status |
| title_full |
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status |
| title_fullStr |
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status |
| title_full_unstemmed |
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status |
| title_sort |
targetable kinase pim1 drives alk inhibitor resistance in high-risk neuroblastoma independent of mycn status |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2019-11-01 |
| description |
Anaplastic lymphoma kinase (ALK) inhibitors are currently being considered in neuroblastoma (NB), but its acquired resistance is reported in non-small cell lung cancers. Here, the authors have found PIM1 overexpression decreases sensitivity to ALK inhibitors in NB and combined ALK and PIM1 inhibition enhances anti-tumour efficacy in vitro and in PDX models. |
| url |
https://doi.org/10.1038/s41467-019-13315-x |
| work_keys_str_mv |
AT rickymtrigg thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT liamclee thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT ninaprokoph thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT leilajahangiri thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT cpatrickreynolds thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT gaamosburke thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT nicolaaprobst thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT miaojunhan thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT jamiedmatthews thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT hongkailim thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT eleanormanners thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT soniamartinez thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT joaquinpastor thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT carmenblancoaparicio thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT olafmerkel thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT inesgarcesdelosfayosalonso thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT petrakodajova thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT simonetangermann thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT sandrahogler thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT jiluo thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT lukaskenner thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT suzannedturner thetargetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT rickymtrigg targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT liamclee targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT ninaprokoph targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT leilajahangiri targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT cpatrickreynolds targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT gaamosburke targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT nicolaaprobst targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT miaojunhan targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT jamiedmatthews targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT hongkailim targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT eleanormanners targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT soniamartinez targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT joaquinpastor targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT carmenblancoaparicio targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT olafmerkel targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT inesgarcesdelosfayosalonso targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT petrakodajova targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT simonetangermann targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT sandrahogler targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT jiluo targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT lukaskenner targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus AT suzannedturner targetablekinasepim1drivesalkinhibitorresistanceinhighriskneuroblastomaindependentofmycnstatus |
| _version_ |
1721446478766931968 |